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DOI 10.1016/j.ccr.2010.03.011SUMMARYImatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients but does not
eliminate leukemia stem cells (LSCs), which remain a potential source of relapse. Here we investigated the
ability of HDAC inhibitors (HDACis) to target CML stem cells. Treatment with HDACis combined with IM
effectively induced apoptosis in quiescent CML progenitors resistant to elimination by IM alone, and
eliminated CML stem cells capable of engrafting immunodeficient mice. In vivo administration of HDACis
with IM markedly diminished LSCs in a transgenic mouse model of CML. The interaction of IM and HDACis
inhibited genes regulating hematopoietic stem cell maintenance and survival. HDACi treatment represents an
effective strategy to target LSCs in CML patients receiving tyrosine kinase inhibitors.INTRODUCTION
Chronic myelogenous leukemia (CML) is a lethal hematological
malignancy resulting from transformation of a primitive hemato-
poietic cell by the BCR-ABL oncogene (Sawyers, 1999).
Leukemia-initiating cells or leukemia stem cells (LSCs) in CML
share several properties with normal hematopoietic stem cells
(HSCs), including the ability to regenerate multilineage hemato-
poiesis and quiescence (Holyoake et al., 1999; Wang et al.,
1998). Progeny of transformed stem cells have a proliferative
advantage over normal hematopoietic cells, allowing the Phila-
delphia (Ph)–positive clone to displace residual normal hemato-
poiesis. Without treatment, CML progresses from a chronic
phase (CP) to an accelerated phase (AP) and terminal blast crisisSignificance
Chronic myelogenous leukemia (CML) results from transforma
BCR-ABL tyrosine kinase inhibitor imatinib mesylate (IM) is
patients with CML but does not eliminate leukemia stem cells (L
relapse and strategies to eliminate residual LSCs are required
tylase inhibitors (HDACis) combined with IM is effective in ind
alone. Several HDACis are in clinical development, and our stud
sine kinase inhibitors to eliminate LSCs in patients with CML.(BC). Deregulated tyrosine kinase activity of the BCR-ABL
protein plays an important role in CML pathogenesis. Treatment
with BCR-ABL tyrosine kinase inhibitors (TKI) reverses the
proliferative advantage of CML progenitors, inducing remission
and allowing regrowth of normal hematopoietic cells. The
BCR-ABL kinase inhibitor imatinib mesylate (IM, Gleevec) has
emerged as the first-line treatment for patients with CML (Druker
et al., 2001; O’Brien et al., 2003). Most patients with CP CML
achieve complete cytogenetic response (CCR) with IM treatment
and demonstrate major reductions in BCR-ABL transcript levels
as assessed by real-time quantitative RT-PCR (Q-PCR) (Hughes
et al., 2003). However, there is evidence that primitive leukemia
stem and progenitor cells are retained in patients achieving
remission with IM treatment (Bhatia et al., 2003). Diseasetion of a hematopoietic stem cell by the BCR-ABL gene. The
effective in inducing remissions and improving survival in
SCs). Patients need continued treatment to prevent disease
. Our studies indicate that treatment with the histone deace-
ucing apoptosis in CML LSCs that resist elimination by IM
ies support clinical trials of HDACis in combination with tyro-
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Figure 1. Effect of IM and LBH Treatment on HDAC Activity and BCR-ABL Expression and Activity in CML CD34+ cells
CD34+ cells from newly diagnosed patients with CML were cultured in the presence of LBH and IM for 24 hr.
(A) Histone proteins were extracted and analyzed by western blotting for levels of acetylated and total Histone H3 and H4.
(B) Total proteins were extracted and analyzed by western blotting for BCR-ABL, P-CrkL, phospho-tyrosine, p27 and p21, and actin. Results for three CML
samples are shown. See also Figure S1.
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HDAC Inhibitors Eliminate LSCsrecurrence is usually seen following cessation of drug treatment,
even in patients with CML who are BCR-ABL negative by Q-PCR
(Cortes et al., 2004; Rousselot et al., 2007). These observations
suggest that ‘‘cure’’ of CML remains elusive following treatment
with TKI alone.
The mechanisms underlying persistence of LSCs in IM-treated
patients with CML are not well understood. BCR-ABL kinase
domain mutations associated with IM resistance may be seen
in some patients with CML in CCR, but are not consistently found
(Chu et al., 2005). Although reduced drug uptake or increased
efflux together with high levels of BCR-ABL expression in prim-
itive progenitors could theoretically contribute to IM resistance,
previous studies have found adequate drug levels and effective
inhibition of BCR-ABL activity in CML progenitors following IM
treatment (Chu et al., 2004; Copland et al., 2006; Jordanides
et al., 2006). Our studies show that IM effectively inhibits prolifer-
ation of CML primitive progenitors but only modestly increases
progenitor cell apoptosis (Graham et al., 2002; Holtz et al.,
2002). Growth factor (GF) or other microenvironmental signals
may preserve viability of CML cells despite BCR-ABL kinase
inhibition by IM (Chu et al., 2004). Importantly, IM-induced
apoptosis is restricted to dividing CML progenitors, whereas
nondividing CML progenitors are especially insensitive to
IM-induced apoptosis (Holtz et al., 2005; Jorgensen et al.,
2005). The relative insensitivity of nondividing CML progenitors
may contribute to the persistence of BCR-ABL+ progenitors in428 Cancer Cell 17, 427–442, May 18, 2010 ª2010 Elsevier Inc.patients achieving remission on IM therapy. Similar results
have been obtained with more potent BCR-ABL TKIs, including
dasatinib, nilotinib, and bosutinib (Copland et al., 2006; Jorgen-
sen et al., 2007; Konig et al., 2008a; Konig et al., 2008b). These
results suggest that BCR-ABL-independent mechanisms
contribute to survival of primitive CML cells after TKI treatment
and indicate the need to identify additional strategies to eliminate
CML LSCs.
Histone deacetylase inhibitors (HDACis) are a class of agents
that have shown promise as a therapy for several cancers (Marks
et al., 2004). HDACis can modulate gene expression through
increased histone lysine acetylation. Anticancer effects may
also be related to modulation of the acetylation status of nonhis-
tone proteins (Bolden et al., 2006). In contrast to most other
proapoptotic agents that preferentially target dividing cells,
HDACis have been shown to induce apoptosis in nonproliferat-
ing cancer cell lines, which may have important implications
for elimination of quiescent primitive LSCs (Burgess et al.,
2004). Treatment with the hydroxamic acid analog pan-HDACi
SAHA, LAQ824 (LAQ), or LBH589 (LBH), alone and in combina-
tion with TKI, has been reported to induce apoptosis in CML cell
lines and BC CML cells (Fiskus et al., 2006a; Fiskus et al., 2006b;
Nimmanapalli et al., 2003a; Nimmanapalli et al., 2003b).
However, BC CML cells may originate from a more mature
progenitor population, rather than a stem cell, and differ mark-
edly in behavior and therapeutic response from CP CML cells
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Figure 2. Apoptosis and Proliferation of
CML andCBCD34+CD38Primitive Progen-
itors and CD34+CD38+ Committed Progeni-
tors Following IM and LBH Treatment
CD34+ cells from newly diagnosed patients with
CML (n = 3) and CB (n = 3) were labeled with
CFSE and CD34+CD38 and CD34+CD38+ popu-
lations selected by flow cytometry sorting. Cells
were exposed to LBH (25 nM or 50 nM), with or
without IM (1 mM) for 96 hr. Apoptosis was
analyzed by flow cytometry as the percentage of
cells labeled by Annexin V-PE. Results for CML
(A) and normal (B) cells are shown. Apoptosis
of undivided cells for samples cotreated with
LBH and 1 mM imatinib are shown for CML
CD34+CD38 and CD34+CD38+ cells in (C) and
for normal cells in (D). Cell divisions were analyzed
by flow cytometry based on reduction in CFSE
intensity, and a proliferation index was determined
using ModFit software. Proliferation indices
were normalized to untreated controls. Results
for CML (E) and normal (F) cells are shown.
Results shown represent mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001, compared with untreated
cells. See also Figure S2.
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HDAC Inhibitors Eliminate LSCs(Calabretta and Perrotti, 2004; Jamieson et al., 2004). The effect
of HDACis on primitive LSCs from CP patients with CML has not
been characterized. It is not known whether HDACis are capable
of inducing apoptosis in quiescent stem and progenitor cells that
resist elimination by BCR-ABL TKI. Here we investigated the
effects of the HDACi, LAQ, and LBH, alone and in combination
with IM, on primitive CML leukemia stem and progenitor cells.
RESULTS
Effect of IM and LBH Treatment on HDAC Activity and
BCR-ABL Expression and Activity in CML CD34+ Cells
We investigated the effects of the HDACi, LBH, and LAQ, alone
and in combination with IM, on CP CML leukemia stem and pro-
genitor cells. We confirmed that exposure to HDACis enhanced
levels of acetylated histones in CML CD34+ cells by western
blotting of chromatin extracts. Acetylated histone H3 and H4Cancer Cell 17, 427–levels were significantly increased in cells
treated with LBH (Figure 1A) or LAQ (Fig-
ures S1A–S1C available online). Histone
acetylation was not altered after treat-
ment with IM alone. Treatment with
HDACis has been reported to reduce
BCR-ABL expression in cell lines and
BC CML cells (Fiskus et al., 2006a; Nim-
manapalli et al., 2003a). We observed
moderate reduction in BCR-ABL protein
levels in CP CML CD34+ cells after treat-
ment with LBH (Figure 1B). Treatment
with IM resulted in reduced tyrosine
phosphorylation of the BCR-ABL sub-
strate CrkL and reduced overall tyrosine
phosphorylation in CML CD34+ cells,
confirming effective inhibition of BCR-ABL kinase activity (Figure 1B). LBH treatment also resulted in
modest reduction in tyrosine phosphorylation in CML CD34+
cells compared with controls, and in further reduction in tyrosine
phosphorylation in combination with IM (Figure 1B). The cell
cycle regulatory genes p21 and p27 are known targets of HDACi
treatment. In our studies, p21 and p27 levels were observed to
be increased in CML CD34+ cells after LBH treatment and further
increased with the combination of LBH and IM (Figure 1B).
Effects of IM and LBH Treatment on CML Progenitor
Apoptosis, Proliferation, and Colony Growth
To determine the effect of LBH on apoptosis and proliferation
of CML progenitor cells, we labeled CML CD34+CD38 and
CD34+CD38+ cells with carboxyfluorescein diacetate succini-
midyl ester (CFSE), cultured them for 96 hr with LBH, IM, or
the combination, and subsequently labeled them with Annexin-
PE and analyzed them by flow cytometry (Figure S2A).442, May 18, 2010 ª2010 Elsevier Inc. 429
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Figure 3. Combination of LBH and IM Eliminates CML Cells Capable of Long-Term Multilineage Engraftment in Immunodeficient Mice
CD34+ cells from CML patients (13 106 to 23 106 cells per mouse) and normal BM (13 105 to 83 105 cells per mouse) were injected into sublethally irradiated
(300 cGy) NSG mice.
(A) Human cell engraftment measured in peripheral blood samples taken from mice (n = 9 for CML; n = 7 for normal) at 4 week intervals by flow cytometric
assessment of human CD45+ cell engraftment is shown.
(B) BM cells were obtained from femurs of mice 16 weeks after transplantation (n = 6 for CML; n = 7 for normal) and specific human cell subsets were detected by
staining with antibodies to human CD34, CD33, CD11b, and CD19. CML CD34+ cells (23 106 cells per mouse, 8 mice per condition) and normal BM CD34+ cells
Cancer Cell
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HDAC Inhibitors Eliminate LSCsAssessment of CFSE fluorescence allowed analysis of cell divi-
sion since fluorescence is reduced by half in successive cell
generations. We observed significantly increased apoptosis of
CML CD34+CD38 primitive and CD34+CD38+ committed pro-
genitors following treatment with the combination of IM and
LBH, but not with IM or LBH alone (Figure 2A). Treatment with
50 nM LBH with or without IM resulted in modest increase in
apoptosis of normal primitive progenitors (Figure 2B). The IM
and LBH combination induced significantly more apoptosis in
CML compared with cord blood (CB) progenitors (CD34+CD38
cells IM plus LBH [25 nM], p < 0.05; IM plus LBH [50 nM],
p < 0.001). Similar results were observed for LAQ (Figures
S2B–S2E). Reduced viability of CML CD34+CD38 and CD34+
CD38+ cells treated with the combination of IM and LBH com-
pared with IM or LBH alone was also observed after trypan
blue labeling (Figure S2P), on evaluation of cell morphology
(Figure S2Q), and by Caspase 3 labeling (Figure S2R).
Previous studies have shown that primitive quiescent CML
CD34+ cells are especially resistant to IM-induced apoptosis
(Graham et al., 2002; Holtz et al., 2005; Holyoake et al., 1999).
We observed that treatment with LBH or LAQ combined with
IM resulted in increased apoptosis of undivided CML CD34+
cells, with CFSE fluorescence equivalent to the parent genera-
tion, compared to IM alone (Figure 2C and Figure S2F). Although
LBH and LAQ treatment also increased apoptosis in undivided
normal progenitor cells compared with IM alone (Figure 2D and
Figure S2G), the increase in apoptosis was significantly less
than in undivided CML progenitor cells (CD34+CD38 cells IM
plus LBH [25 nM], p < 0.01; IM plus LBH [50 nM], p < 0.01). In
conclusion, the combination of IM and LBH effectively induces
apoptosis in CML primitive and committed progenitors, and to
a significantly greater extent than in normal progenitors.
Treatment of CML CD34+CD38 primitive and CD34+CD38+
committed progenitors with IM or the combination of IM and
LBH resulted in significant inhibition of proliferation as measured
by reduction in CFSE fluorescence, whereas only modest reduc-
tion in proliferation of CML CD34+CD38 cells was seen with
LBH589 alone (Figure 2E). Treatment with LBH alone did not
inhibit normal progenitor proliferation, whereas the combination
of LBH and IM also resulted in modest inhibition of CB progenitor
proliferation. Significantly greater proliferation inhibition of CML
compared with CB CD34+CD38 cells was seen for IM and IM
combined with LBH 50 nM (p < 0.05) (Figure 2F). Similar results
were seen with LAQ (Figures S2H–S2K).
The effect of LAQ on CML and normal committed progenitor
frequency was assessed in methylcellulose progenitor assays
(Figures S2L–S2O). Significant reduction of CML CFC frequency
was seen with IM and at the highest LAQ concentration (100 nM;
p < 0.001). LAQ combined with IM resulted in enhanced inhibition(1 3 105 cells per mouse, seven mice per condition) were cultured for 96 hr in t
in combination with LBH and then transplanted into NSG mice. Mice were euth
cytometry.
(C and G) Representative results of engraftment in BM for CML are shown in (C)
(D and H) Combined results for engraftment of cells in BM for CML are shown in
samples. Human CD45+ cells were enriched from BM of mice engrafted with CML
CD45+ cells present in column-selected cells were as follows: untreated, 43.9%
(E) CD45+ selected cells (1 3 105) were plated in CFC assay with human specific
(F)BCR-ABLmRNA levels in CD45+ selected cells were measured by Q-PCR. Res
with untreated cells. See also Figure S3.of CML CFC numbers compared with LAQ alone or IM alone
(p < 0.05). High concentration of LAQ also resulted in reduction
in normal CFC growth, which was not enhanced by combination
of IM with LAQ.
Effect of IM and LBH on CML Cells Capable
of Engraftment in Immunodeficient Mice
The immunodeficient nonobese diabetic/severe combined
immune deficiency (NOD.CB17-Prkdcscid or NOD/SCID) mouse
model is widely used to assay primitive human hematopoietic
stem cells with in vivo engraftment capacity (SCID-repopulating
cells or SRC) (Larochelle et al., 1996).
NOD/SCID interleukin-2 receptor-g chain (IL2Rg)-deficient
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz or NSG) mice support superior
engraftment of human hematopoietic cells compared with NOD/
SCID mice (Shultz et al., 2005). We determined that larger
numbers of CML CD34+ cells (13 106 to 23 106) were required
to establish engraftment in NSG mice compared to CD34+ cells
from normal bone marrow (BM) (13 105 to 83 105). Interestingly
CML LSCs demonstrated enhanced short-term compared
with long-term engraftment and increased myeloid skewing
compared with normal HSCs (Figures 3A and 3B).
We tested the effect of IM (1 mM), LBH (50 nM), or LBH in
combination with IM (1 mM) on CML and normal cells capable
of engraftment in NSG mice at 16 weeks. We observed reduced
engraftment of CML CD34+ cells treated with IM alone (p < 0.05)
and LBH alone (p < 0.001) compared to untreated controls.
However, treatment with the combination of IM and LBH resulted
in further inhibition of engraftment of CML CD34+ cells compared
with no treatment (p < 0.001), IM alone (p < 0.05), and LBH alone
(p < 0.05) and indeed abrogated CML cell engraftment in mice
(Figures 3C and 3D). Engraftment of both myeloid and lymphoid
cells was eliminated (not shown). Human CFC were also elimi-
nated from the marrow of mice receiving cells treated with LBH
combined with IM (p < 0.01, p < 0.05, and p < 0.01 compared
with no treatment, IM alone, and LBH alone, respectively) (Fig-
ure 3E). FISH analysis showed that 86% of human cells from
controls engrafted in mice were BCR-ABL+ confirming that
engraftment is truly CML in origin. Sufficient numbers of cells
were not available to perform FISH analysis after combination
treatment. Q-PCR analysis confirmed that BCR-ABL+ LSCs
contributed to engraftment of human cells. BCR-ABL and BCR
signal were not detectable in mice receiving cells treated with
the combination, confirming abrogation of engraftment of human
CML cells (Figure 3F). CB CD34+ cells showed significantly
reduced engraftment after treatment with IM alone, LBH alone,
or the combination of IM and LBH compared with no treatment
(p < 0.001 each). Treatment with LBH and IM combination did
not result in significantly enhanced inhibition of engraftmenthe absence of drug (control), with IM (1 mM) alone, LBH (50 nM) alone, or IM
anized after 16 weeks, and PB, BM, and spleen cells were analyzed by flow
and for CB in (G).
(D) and for CB in (H). Results shown represent the mean ± SEM for multiple
CD34+ cells with immunomagnetic column selection. The percentage of human
± 2.6%; IM, 20.9% ± 6.3%; LBH, 5.5% ± 1.5%; and IM plus LBH, 0.
growth factors.
ults shown represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, compared
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Figure 4. In Vivo Administration of LBH and IM Inhibits Myeloproliferation and Induces Apoptosis in LSCs in Transgenic BCR-ABL–Express-
ing Mice
BCR-ABL expression was induced in Scl-tTa-BCR-ABL/GFP mice by tetracycline withdrawal. BM cells were obtained 4 weeks after induction, and GFP-express-
ing cells selected using flow cytometry were transplanted into wild-type FVB/N recipient mice irradiated at 900 cGy (106 cells /mouse). Treatment with IM
Cancer Cell
HDAC Inhibitors Eliminate LSCs
432 Cancer Cell 17, 427–442, May 18, 2010 ª2010 Elsevier Inc.
Cancer Cell
HDAC Inhibitors Eliminate LSCscompared to IM alone (p = 0.37) or LBH alone (p = 0.43) (Figures
3G and 3H). Significantly less inhibition of normal cell engraft-
ment was seen after LBH and IM treatment compared to CML
cell engraftment, which was completely eliminated (p = 0.01).
Similar results were obtained when evaluating the effect of
LAQ treatment on engraftment of CML and normal cells in
NSG mice at 6 weeks (Figures S3A–S3E). These results show
that HDACis in combination with IM effectively target primitive
CML cells capable of multilineage engraftment that resist elimi-
nation following treatment with IM alone.
Effect of In Vivo Administration of LBH
and IM on Leukemia Stem Cells
in Transgenic BCR-ABL-Expressing Mice
The low levels of long-term engraftment of CML LSCs in the
xenogeneic transplant model limit its use for in vivo drug treat-
ment studies. We therefore utilized a transgenic Scl-tTa-BCR-
ABL mouse model to investigate the effect of HDACi treatment
on CML stem cells in vivo (Huettner et al., 2003). Withdrawal
of tetracycline results in reversible induction of BCR-ABL
expression and induction of a CML-like myeloproliferative
disorder characterized by neutrophilic leukocytosis and spleno-
megaly. Transplantation of leukemic BM cells to wild-type recip-
ients consistently resulted in development of a myeloproliferative
disorder 3–4 weeks after transplantation. The transplantation
approach allows generation of a large cohort of mice with similar
time of onset of leukemia, providing a robust and consistent CML
model suitable for preclinical studies of therapeutic interventions
against CML stem cells in the setting of the in vivo host microen-
vironment.
Scl-tTa-BCR-ABL mice were crossed with transgenic GFP-
expressing mice to facilitate identification of donor cells. BM cells
were obtained from Scl-tTa-BCR-ABL/GFP mice 4 weeks after
induction of BCR-ABL expression by tetracycline withdrawal.
GFP-expressing cells were selected using flow cytometry and
transplanted into wild-type FVB/N recipient mice irradiated at
900 cGy. Recipient mice developed leukocytosis and neutro-
philia 4 weeks after transplantation. Mice were then treated for
4 weeks with IM (200 mg/kg body weight daily by gavage), LBH
(30 mg/kg body weight intraperitoneally 3 days per week on
Monday, Wednesday, and Friday), LBH in combination with IM,
or vehicle alone (controls). Mice treated with the IM and LBH
combination demonstrated significantly increased apoptosis of
Lin-Sca-1+Kit+ (LSK) stem cells compared with vehicle or either
drug alone (p < 0.005 Figures 4A and 4B). In vivo EdU labeling
studies showed reduction in the percentage of LSK cells in
S-phase in mice treated with the combination of IM and LBH
and to a lesser extent with IM (Figure 4C). Levels of white
blood cells (WBCs), neutrophils, and GFP+ cells (representing(200 mg/kg daily by gavage), LBH (30 mg/kg body weight intraperitoneally 3 days p
vehicle alone (controls) was initiated 4 weeks after transplantation and continue
treatment by Annexin-V and DAPI labeling.
(A and B) Representative results are shown in (A), and compiled results from thre
(C) For evaluation of stem cell cycling, mice were injected intraperitoneally with Ed
on the basis of EdU incorporation in BM LSK cells measured by flow cytometry as
such experiments are shown.
(D–H) PB total WBC counts (D), neutrophil percentage and absolute neutrophil co
measured 4 weeks after start of treatment. Results represent the mean ± SEM for
no treatment.BCR-ABL expressing cells) were elevated in controls but were
reduced to normal levels in mice receiving the different treat-
ments (Figures 4D–4H). LBH combined with IM resulted in greater
reduction in WBC, neutrophils, and GFP+ cells than single agent
LBH or IM. Control mice became moribund, and three of ten mice
died between 3 and 4 weeks after start of treatment (7–8 weeks
after transplantation), whereas the mice receiving the different
treatments remained well. Mice were euthanized at 4 weeks
and BM and spleen cells were analyzed by flow cytometry.
A profound reduction of GFP+ WBCs (Figure 5B), myeloid cells
(Gr-1+Mac-1+, Figure 5C), granulocyte-macrophage progenitors
(GMP, Lin-Kit+Sca-1-CD34+FcgRII/IIIhi, Figure 5D), common
myeloid progenitors (CMP, Lin-Kit+ Sca-1-CD34+FcgRII/IIIlo,
Figure 5E), and stem cells (LSK cells, Figures 5F and 5G) was
observed in the BM of mice treated with IM combined with LBH
compared with IM or LBH alone. LBH as a single agent also
reduced GFP+ WBCs and progenitors but to a significantly lesser
extent than the combination. A marked reduction of total GFP+
WBCs (Figure 5H), immature myeloid cells (Gr-1+Mac-1+)
(Figure 5I), GMP (Figure 5J), CMP (Figure 5K), and LSK cells
(Figures 5L and 5M) was also seen in spleens of mice treated
with IM in combination with LBH. In contrast to effects on BM
cells, LBH as a single agent was ineffective in reducing numbers
of GFP+ progenitors in the spleen. Treatment of wild-type FVBN
mice with IM, LBH, or the combination for 4 weeks did not cause
clinical symptoms or affect survival. There was a trend toward
less weight gain in treated mice compared with controls,
although it was not statistically significant (Figure S4A). Treat-
ment with LBH or LBH combined with IM caused moderate
suppression of WBC and red blood cell (RBC) counts in periph-
eral blood and suppression of GMP, MEP, and LSK cells in BM
from wild-type mice (Figures S4B–S4G). Therefore, LBH with or
without IM results in moderate in vivo toxicity to normal hemato-
poietic cells, although considerably less than the toxicity to
leukemia cells.
We conducted survival studies on mice after 4 weeks expo-
sure to treatment (Figure 6A). Control mice that survived the 4
weeks treatment period all died within 90 days after discontinu-
ing treatment (Figure 6B). Mice treated with the combination of
IM and LBH showed markedly improved survival, and showed
normal WBC counts at 8 weeks after discontinuation of treat-
ment with only small number of residual GFP+ WBCs (Figure 6C
and 6D). To accurately quantify the loss of CML stem cells, we
transplanted BM cells from leukemic mice treated with IM,
LBH, or the combination for 4 weeks in limiting dilutions to
secondary mice (Figure 6E). Treatment with the combination of
LBH and IM resulted in abrogation of engraftment of GFP+
leukemia cells in secondary mice measured at 8 and 16 weeks
after transplantation (Figure 6F–6H). In contrast, LBH alone orer week on Monday, Wednesday, and Friday), or LBH in combination with IM or
d for 4 weeks. Apoptosis in BM LSK cells was evaluated 5 days after start of
e experiments are shown in (B).
U and killed 2 hr later. The percentage of stem cells in S-phase was determined
described in Experimental Procedures. Representative results from one of two
unts (E and F), and GFP+ WBC percentage and absolute counts (G and H) were
five to six mice per treatment. *p < 0.05, **p < 0.01, ***p < 0.001, compared with
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Cancer Cell
HDAC Inhibitors Eliminate LSCsIM alone did not significantly affect levels of GFP+ cells in
secondary recipients (Figure 6F) or the frequency of LSCs
quantified on limiting dilution analysis (Figures 6G and 6H). These
results clearly demonstrate that the LBH and IM combination
is capable of markedly reducing the number of LSCs capable
of engraftment in secondary recipients and causing disease
relapse.
Effect of IM and LBH on Gene Expression
in CML Progenitors
To further investigate potential mechanisms underlying CML
LSC targeting, we conducted gene expression analysis of CML
CD34+CD38 cells exposed to IM, LBH, and the combination
of IM and LBH. We focused our analysis on genes whose expres-
sion was significantly affected by the combination of IM and
HDACis, compared with IM and HDACis alone, which we refer
to as the ‘‘interaction’’ of IM and LBH (Figure 7A). The gene
expression programs represented by these genes were identi-
fied with Gene Set Enrichment Analysis (GSEA). IM and LBH
combination resulted in increased inhibition of HDACi-downre-
gulated gene sets compared to LBH alone, suggesting that
cotreatment with IM could potentiate HDACi-induced gene
expression alterations. We observed reduced expression of
gene sets related to the HSC state; the HOX-, MYC-, and
WNT-related pathways; cell-cycle regulation; protein translation
through the mTOR-EIF4 pathway; cellular stress response and
cell survival; and increased expression of G protein-coupled
receptor genes (Figure 7B and Table 1). We also observed
reduced expression of genes with transcription factor (TF)
binding motifs for E2F, which has important roles in regulating
cell-cycle progression and apoptosis (Chen et al., 2009); Ying-
Yang 1, which directs histone acetylation changes at promoters
(Gordon et al., 2006); GABP/NRF2 and NRF1, which regulate
stress response (Mathers et al., 2004); and MYC-MAX, which
regulate HSC proliferation and maintenance (Laurenti et al.,
2008) (Table 1). These results suggest possible molecular mech-
anisms that may contribute to the effects of the HDACi and IM
combination (Figure 7C).
DISCUSSION
Several leukemias, including CML, are propagated by small pop-
ulations of LSCs, eradication of which may be required to
achieve long-term remission and cure. Populations of cancer
stem cells have also been identified in several solid tumors
(Clarke et al., 2006). Treatment with BCR-ABL TKI, including
IM, nilotinib, and dasatinib, reverses the proliferative advantage
of CML progenitors, resulting in remission induction, but doesFigure 5. LBH and IM Administration Profoundly Depletes Leukemia
BCR-ABL–Expressing Mice
(A) Mice from the cohort described in Figure 4 were euthanized after 4 weeks of
spleen cells were obtained). GFP-expressing hematopoietic populations were an
(B–F) Results for the following GFP+ populations in the BM (n = 6 mice per treatme
GMP (D), CMP (E), and LSCs (LSK cells) (F).
(G) Representative flow cytometry plot for BM LSK cells is shown.
(H–L) Results for GFP+ populations in the spleens (n = 5 mice per treatment) are as
cells (L).
(M) A representative flow cytometry plot for splenic LSK cells is shown. Results rep
compared with no treatment. See also Figure S4.not eliminate LSCs, which continue to be detectable in patients
despite prolonged IM treatment. Persistent LSCs represent
a reservoir of disease and potential source of relapse. Patients
with CML have a high likelihood of disease relapse on discontin-
uation of treatment, and it is currently recommended that
patients should be treated with IM indefinitely to prevent relapse.
Concerns regarding the lack of disease cure with IM alone, the
potential risk of adverse effects with long-term treatment, issues
of noncompliance, and the high financial burden associated with
drug treatment provide a strong impetus to develop strategies to
target residual LSCs.
In the current study, we found that treatment with HDACis in
combination with IM was significantly more effective in inducing
apoptosis in CP CML progenitor cells compared with IM alone.
The combination of HDACis and IM induced apoptosis in quies-
cent CML progenitor cells that are highly resistant to elimination
following treatment with IM alone. HDACis in combination with
IM also inhibited CML progenitor proliferation and CML
committed progenitor growth in colony assays. In contrast to
reports that HDACis could induce apoptosis in CML cell lines
and BC CML cells (Fiskus et al., 2006a; Fiskus et al., 2006b; Nim-
manapalli et al., 2003a; Nimmanapalli et al., 2003b), we found that
HDACis by themselves had minimal effect on apoptosis of CP
CML cells. CML progenitor proliferation and CFC frequency
were reduced only at the highest HDACi concentrations. There-
fore, targeting of primitive CP CML cells by HDACis is potentiated
by concomitant inhibition of BCR-ABL tyrosine kinase activity.
Importantly, treatment with the combination of HDACis and IM
markedly depleted CML LSCs capable of long-term, multilineage
engraftment in immunodeficient mice. Furthermore, administra-
tion of the HDACis and IM in combination resulted in profound
depletion of LSCs with secondary repopulating capacity in the
in vivo setting in a transgenic BCR-ABL mouse model of CML,
and prevented leukemia relapse after discontinuation of treat-
ment. Therefore, our data consistently show that the combination
of IM with an HDAC inhibitor effectively targets primitive CML
LSCs and is superior to either agent alone. On the other hand,
this combination may be less suitable for treating patients
harboring IM resistance-conferring BCR-ABL mutations, since
the mutant kinase would be inhibited poorly by IM, thus elimi-
nating its required contribution to the effect of the combination.
The effects of HDACis are complex and involve multiple genes
and pathways. HDACi-induced reduction in BCR-ABL protein
expression and kinase activity could potentiate the effects of
IM on CML LSCs. We also observed that combination with IM
enhanced HDACis-induced gene expression changes, com-
pared with HDACis alone. Although the mechanisms underlying
this effect are still unknown, novel nuclear functions ofStem and Progenitor Cells in the BM and Spleen of Transgenic
treatment with IM, LBH, IM combined with LBH, or vehicle alone and BM, and
alyzed by flow cytometry.
nt) are shown: total GFP+ WBCs (B), immature myeloid cells (Gr-1+Mac-1+) (C),
follows: total GFP+ WBCs (H), Gr-1+Mac-1+ cells (I), GMP (J), CMP (K), and LSK
resent the mean ± SEM for multiple samples. *p < 0.05, **p < 0.01, ***p < 0.001,
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Figure 6. Transplantation of BM from IM and LBH Treated Mice into Secondary Recipients
(A) BCR-ABL expression was induced in GFP+/SCLtTA/BCR-ABL mice, and BM cells were obtained from mice 4 weeks after induction. GFP-expressing cells
were selected and transplanted into wild-type FVB/N recipient mice (106 cells/mouse). Treatment with IM, LBH, LBH in combination with IM, or vehicle alone was
initiated 4 weeks after transplantation and was continued for 4 weeks (eight mice per condition) as described for Figures 4 and 5.
(B) Mice were followed after discontinuation of treatment and survival was monitored for 90 days.
(C and D) The total WBC count (C) and GFP+ WBC count (D) in PB of mice 8 weeks after discontinuation of treatment are shown.
(E) BCR-ABL expression was induced in GFP+/SCLtTA/BCR-ABL mice, and BM cells were obtained 4 weeks after induction. GFP-expressing cells were
transplanted into wild-type FVB/N recipient mice irradiated at 900 cGy (106 cells/mouse). Treatment with IM, LBH, and LBH in combination with IM, or vehicle
alone was initiated 4 weeks after transplantation and continued for 4 weeks (five mice per condition). Mice were then euthanized, and BM cells were obtained.
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Cancer Cell
HDAC Inhibitors Eliminate LSCscytoplasmic tyrosine kinases related to histone and transcription
factor modulation have been recognized. Potential mechanisms
involved in CML LSC inhibition by the IM and HDACi combina-
tion, compared with IM or HDACis alone, suggested by gene
expression analyses included reduced expression of genes
related to the primitive HSC state such as downregulation of
HOX-, MYC-, and WNT-related genes; reduced expression of
E2F-regulated genes, which may play an important role in pro-
tecting nonproliferating cells from stress-induced apoptosis
(Moon et al., 2005); and increased G protein coupled receptor
expression, possibly influencing microenvironmental interac-
tions of CML progenitors (Figure 7C). These observations,
although preliminary, indicate promising avenues for further
investigation of molecular mechanisms underlying the effects
of the HDACi and IM combination.
Our studies indicate significant activity of HDACis against
normal hematopoietic progenitors with increased levels of
apoptosis, inhibition of proliferation, and inhibition of CFC and
SRC growth. In vivo administration of LBH was associated with
moderate inhibition of normal blood cell counts and BM stem
and progenitor populations and reduced weight gain. On the
one hand, these inhibitory effects on normal progenitors are
consistent with clinical observations of thrombocytopenia and
myelosuppression in clinical trials of LBH (Bruserud et al.,
2007). On the other hand, the HDACi and IM combination
resulted in significantly less apoptosis of normal compared
with CML progenitors and significantly less inhibition of normal
SRC compared with CML SRC. In addition, in vivo administration
of the combination resulted in significantly less inhibition of
normal blood cell counts, and BM stem and progenitor popula-
tions, compared with near complete elimination of CML LSCs.
These observations suggest a therapeutic window for HDACi
and IM effects on CML LSCs compared with normal stem cells
that could be exploited clinically. However, the toxicity of LBH
to normal progenitors indicates a need for continued exploration
of mechanisms underlying activity of the LBH and IM combina-
tion on CML LSCs to aid development of more selective,
nontoxic approaches for targeting LSCs in future.
There is considerable interest in devising improved
approaches to target CML LSCs. The therapeutic application
of these studies will be toward using a combination of LBH
and IM to achieve elimination of residual LSCs in IM-treated
and responsive patients with CML. We have recently shown
that a farnesyltransferase inhibitor BMS-214662 can selectively
kill quiescent primitive CML progenitor cells (Copland et al.,
2008). However, this agent is not being developed for clinical
testing in CML. In contrast, several HDACis are currently in clin-
ical trials for hematological malignancies as well as solid tumors
(Glaser, 2007). The role of HDACis in targeting cancer stem cells
has not been previously described. On the basis of our observa-
tion that LAQ and LBH combined with IM can eliminate CMLThe BM cells were pooled from 3–5 mice, and 23 106, 13 106, or 53 105 cells/m
from wild-type FVBN mice were transplanted into wild-type FVB/N recipient mice i
The percentage of GFP+ cells in PB was analyzed by flow cytometry.
(F) The mean ± SEM of GFP+ WBCs at 8 and 16 weeks after transplantation are
engraftment.
(G) The frequency of LSCs after treatment is shown.
(H) The fraction of mice showing evidence of engraftment at 16 weeks after secoLSCs, we have developed and initiated a clinical trial to deter-
mine the safety and tolerability of LBH in combination with IM
in patients with CML who are in cytogenetic remission with
evidence of residual BCR-ABL+ cells. The ultimate measure of
success for these studies in achieving elimination of residual
LSCs will be the ability of patients to maintain long-term remis-
sion after discontinuation of IM treatment. Historically, studies
in CML have greatly enhanced our understanding of chromo-
somal translocations and oncogenes in cancer biology and
have led the way in successful application of targeted therapies.
It remains to be determined whether the current studies of
targeting of LSCs in CML using HDACis will have broader appli-
cation to targeting of primitive, quiescent cancer-initiating cells
in other leukemias and solid tumors.
EXPERIMENTAL PROCEDURES
Samples
CB samples were kindly provided by StemCyte (Arcadia, CA). Normal BM
samples were obtained from donors at City of Hope National Medical Center
(COHNMC). Mononuclear cells were isolated using Ficol separation. CD34+
cells were then isolated using a positive magnetic bead selection protocol
(StemCell Technologies, Vancouver, BC, Canada). CML samples were ob-
tained from patients in CP who had not received prior IM treatment from the
COHNMC and Glasgow University. BM samples were processed as described
above. Leukopheresis samples were processed for CD34+ cell selection with
CliniMACS (Miltenyi Biotech, Germany). CD34+CD38 and CD34+CD38+ cells
were obtained by flow cytometry sorting. All patients and healthy donors
signed an informed consent form. Sample acquisition was approved by the
Institutional Review Boards at the COHNMC, in accordance with an assurance
filed with and approved by the Department of Health and Human Services, and
the North Glasgow University Hospital Division of NHS Greater Glasgow and
Clyde, and met all requirements of the Declaration of Helsinki.
Cell Culture
Cells were exposed to IM, LBH, and LAQ (Novartis) during culture in Stemspan
serum-free medium (StemCell Technologies), supplemented with low concen-
trations of growth factors (GF) similar to those present in long-term BM
culture stroma-conditioned medium (200 pg/mL granulocyte-macrophage
colony-stimulating factor [GM-CSF], 50 pg/mL leukemia inhibitory factor
[LIF], 1 ng/mL granulocyte colony-stimulating factor [G-CSF], 200 pg/mL
stem cell factor [SCF], 200 pg/mL macrophage-inflammatory protein-1a
[MIP-1a], and 1 ng/mL interleukin-6 [IL-6]) at 37C with 5% CO2 and high
humidity (Bhatia et al., 1995).
Analysis of Proliferation and Apoptosis
Cells were labeled with 1.25 mM CFSE (Molecular Probes, Eugene, OR) for
10 min at 37C, were incubated overnight in Stemspan serum-free medium
supplemented with low concentrations of growth factors, as described above,
for releasing unbound CFSE, were labeled with CD34-APC and CD38-PE, and
were flow-cytometry sorted (MoFlo; Cytomation, Fort Collins, CO) for
CD34+CD38 and CD34+CD38+ cells with narrow and uniform CFSE labeling.
Cells were then cultured as described above for 96 hr with or without IM, LBH,
or LAQ, were labeled with Annexin V-PE (BD-PharMingen, San Diego, CA), and
were analyzed by flow cytometry (FACSCalibur; BD) for Annexin V and CFSE
fluorescence. The level of CFSE in the parent cells was determined usingouse (eight mice per dose per condition) mixed with 23 105 BM cells/mouse
rradiated at 900 cGy. Engraftment was monitored by drawing PB every 4 weeks.
shown. A percentage of GFP+ cells in PBR0.5% was considered positive for
ndary transplantation is shown.
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HDAC Inhibitors Eliminate LSCsaliquots of cells fixed in 4% paraformaldehyde directly after cell sorting. Mod-
Fit software (Verity, Topsham, ME) was used for assessment of the different
cell generations and proliferation index of each sample. The percentage of
apoptotic cells in total, divided, and undivided cells was determined. The
effect of drug treatment on cell viability was also assessed by trypan blue
staining, assessment of cell morphology and Caspase 3 labeling as described
in the Supplemental Experimental Procedures.
Engraftment of Human Cells in Immunodeficient Mice
CML CD34+ cells (1–2 3 106 cells/ mouse) or CB CD34+ cells (1 3 105 cells/
mouse) were cultured for 96 hr in the absence of drug (control), or with addition
of IM (1 mM) alone, LBH (50 nM) alone, or IM (1 mM) in combination with LBH or
LAQ (50 nM) in medium with low concentrations of GF. Cells were then
harvested, washed, and transplanted via tail vein injection into sublethally
irradiated (300 cGy) 8-week-old NOD.Cg-Prkdcscid IL2rgtm1Wjl /SzJ mice
(NSG mice, Jackson Laboratory, Bar Harbor, ME). Mice were euthanized after
6 or 16 weeks, and marrow contents of femurs, spleen cells, and blood cells
were obtained at necropsy. For assessing human cell engraftment, cells
were labeled with anti-human CD45 antibody and analyzed by flow cytometry.
Specific human cell subsets were detected by staining with antibodies to
human CD34, CD33, CD11b, and CD19. Human CD45+ cells were selected
by immunomagnetic column selection. For assessing human CFC, CD45+
selected cells were placed in methylcellulose progenitor culture with human
specific cytokines. For assessing engraftment of malignant BCR-ABL–
expressing cells, CD45+ selected cells obtained were evaluated for the
BCR-ABL translocation by interphase FISH and for BCR-ABL mRNA levels
by Q-PCR. Mouse care and experimental procedures were performed in
accordance with established institutional guidance and approved protocols
from the Institutional Animal Care and Use Committee of Beckman Research
Institute at COHNMC.
In Vivo Treatment of Transgenic BCR-ABL Mice
Inducible, transgenic Scl-tTa-BCR-ABL mice in the FVB/N background
(Huettner et al., 2003) were crossed with transgenic GFP-expressing mice
(FVB.Cg-Tg [ACTB-EGFP] B5Nagy/J, Jackson Laboratories). BM cells were
obtained from Scl-tTa-BCR-ABL/GFP mice 4 weeks after induction of
BCR-ABL expression by tetracycline withdrawal, and a pure population of
GFP-expressing cells was selected with flow cytometry and was transplanted
by tail vein injection (106 cells/mouse) into wild-type FVB/N recipient mice irra-
diated at 900 cGy. Blood samples were obtained 4 weeks after transplantation
to confirm development of neutrophilic leukocytosis. Mice were treated with
IM (200 mg/kg daily by gavage for 28 days), LBH (30 mg/kg body weight intra-
peritoneally three times a week for 28 days), LBH in combination with IM, or
with vehicle alone (control). After 4 weeks of treatment, animals were eutha-
nized, and the total marrow content of femurs and tibiae and spleen cells
were obtained. The number of total nucleated cells, GFP-expressing cells,
and GFP+ myeloid, progenitor, and stem cell populations were measured by
flow cytometry, as described in Supplemental Experimental Procedures. The
effect of drug administration on apoptosis and cycling of stem cells in vivo
was evaluated as described in the Supplemental Experimental Procedures.
BM cells from a subset of treated mice were pooled and 2 3 106, 1 3 106,
5 3 105 cells/mouse (eight mice per dose per condition) mixed with 2 3 105
BM cells/mouse from wild-type FVBN mice were transplanted into wild-type
FVB/N recipient mice irradiated at 900 cGy. Engraftment was monitored byFigure 7. Gene Expression Changes Induced by Combined IM and LBH
CD34+CD38 cells from three patients with CML were selected with flow cytome
of IM and LBH or without exposure to drugs (controls) for 24 hr. RNA was extrac
Microarray data analyses were performed, and differentially expressed genes w
(A) The log2 fold changes in gene expression after IM, LBH, and IM plus LBH treatm
the fold elevation or reduction of gene expression with the IM+LBH combination co
shown are those whose expression is significantly altered as a result of the inter
(B) GSEA was performed to detect enrichment of predetermined gene sets after I
for these gene sets are shown. The column labeled ‘‘interaction’’ shows gene sets
of the interaction between IM and LBH. The highest ranked gene sets within the m
sets per category).
(C) A summary of regulatory mechanisms that are significantly affected by the indrawing peripheral blood (PB) every 4 weeks. The percentage of GFP+ cells
in PB was analyzed by flow cytometry. The fraction of mice showing evidence
of engraftment at 16 weeks after secondary transplantation was determined,
and the frequency of LSCs was calculated using Poisson statistics. Another
subset of mice was followed after discontinuation of treatment, and survival
and PB counts were monitored for 90 days. Mouse care and experimental
procedures were performed under pathogen-free conditions in accordance
with established institutional guidance and approved protocols from the Insti-
tutional Animal Care and Use Committee of Beckman Research Institute at
COHNMC.
Real-Time Q-PCR Analysis
For measuring BCR-ABL mRNA in cells engrafted in mice, total RNA was
extracted with the RNeasy Mini Kit (QIAGEN, Valencia, CA), and first-strand
cDNA was synthesized with Superscript III first strand kit and Q-PCR analysis
performed with primer and probe sequences for BCR-ABL (B3A2), as
described elsewhere (Branford et al., 1999). BCR levels were measured as
internal controls. The amount of BCR-ABL mRNA per unit input RNA was
calculated on the basis of the standard curves.
Western Blotting
Cells were cultured with or without IM, LBH, and LAQ for 24 hr. For analysis
of histones, cells were lysed in buffer containing 0.5% Triton X-100, 2 mM
phenylmethylsulfonyl fluoride (PMSF), and 0.02% sodium azide; chromatin
was isolated with centrifugation, and histones were extracted overnight in
0.2 N HCl. For evaluation of other proteins, cells were lysed in buffer containing
0.5% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM PMSF, 50 mM NaF,
1 mM Na3VO4, and a protease inhibitor cocktail (all from Sigma Diagnostics).
Proteins were resolved on 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gels and were transferred to nitrocellulose mem-
brane. Membranes were sequentially reprobed with primary and secondary
antibodies. Primary antibodies included anti-Histone-H3 and anti-Histone-
H4 rabbit polyclonal and anti-acetyl-Histone-H3 (Lys9/Lys14) rabbit polyclonal
antibody (9715 and 9677) (Cell Signaling Technology, Danvers, MA), anti-
acetyl H4 (Millipore, Billerica, MA), anti-P-CrkL (Cell Signaling Technology),
anti-phosphotyrosine (Upstate), anti-P27 (c-19) and anti-P21(C-19) (Santa
Cruz Biotechnology, Santa Cruz, CA), anti-actin mouse monoclonal antibody
(AC-15) (Sigma-Aldrich Corp., St. Louis, MO), and anti-ABL (Ab-3) (Oncogene
Science, Cambridge, MA). Horseradish peroxidase–conjugated secondary
antibodies were from Jackson ImmunoResearch Laboratories (Westgrove,
PA). Antibody detection was performed with the Superfemto kit (Pierce
Biotechnology, Rockford, IL). Protein levels were determined by densitometry
with Image-Quant software (Amersham Pharmacia Biotech, Piscataway, NJ).
Analysis of Gene Expression Changes Induced by Combined IM
and LBH Treatment
CML CD34+CD38 cells selected with flow cytometry sorting were treated
with IM (1 mM), LBH (50 nM), and the combination of IM and LBH or cultured
without exposure to drugs (controls) for 24 hr (n = 3 each). Total RNA from
5000 cells was extracted with the RNeasy kit (QIAGEN), was amplified and
labeled with GeneChip Two-Cycle Target Labeling and Control Reagents
(Affymetrix, Santa Clara, CA), and was hybridized to Affymetrix GeneChip
Human Genome U133 Plus 2.0 Arrays. Microarray data analyses were
performed with R (version 2.9) with genomic analysis packages fromTreatment
try sorting and were cultured with IM (1 mM), LBH (50 nM), or the combination
ted, amplified, labeled, and hybridized to Affymetrix HG U133 plus 2.0 Arrays.
ere identified as described in Experimental Procedures.
ent compared to controls are shown. The column labeled ‘‘interaction’’ shows
mpared to the sum of the effects of IM given alone and LBH given alone. Genes
action between IM and LBH (p < 0.01; fold changeR 3).
M, LBH, and combination treatment. The normalized enrichment scores (NES)
that are enriched for genes whose expression is significantly altered as a result
ost common functional categories are displayed (FDR < 0.1 with up to 10 gene
teraction of LBH and IM is shown.
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Table 1. Results of Gene Set Enrichment Analysis
Gene Sets enriched by Interaction
between IM and LBH NES FDR q-val
Gene Set Name
GPCRS_CLASS_A_RHODOPSIN_
LIKE
2.334226 <1.00E-05
GPCRDB_CLASS_A_RHODOPSIN_
LIKE
2.423674 <1.00E-05
STEMCELL_COMMON_UP 2.4496958 <1.00E-05
HSC_INTERMEDIATEPROGENITORS_
SHARED
2.3206468 <1.00E-05
RIBOSOMAL_PROTEINS 2.4317436 <1.00E-05
TRANSLATION_FACTORS 2.3928194 <1.00E-05
UVC_XPCS_ALL_DN 2.4149804 <1.00E-05
UVC_HIGH_ALL_DN 2.4105043 <1.00E-05
REN_E2F1_TARGETS 2.1447365 <1.00E-05
HDACI_COLON_BUT16HRS_DN 2.1105642 0.000194
DNA_REPLICATION_REACTOME 2.0854743 0.000532
HDACI_COLON_BUT12HRS_DN 2.0248308 0.001158812
CHEN_HOXA5_TARGETS_UP 1.9763813 0.001988439
DORSAM_HOXA9_UP 1.9619048 0.001844117
MYC_TARGETS 1.8888725 0.004696284
SANSOM_APC_LOSS5_UP 1.8862375 0.005068596
MENSSEN_MYC_UP 1.8385748 0.008161867
HSA04210_APOPTOSIS 1.7196336 0.019393332
KENNY_WNT_DN 1.6921147 0.024098977
FASPATHWAY 1.6343089 0.035348434
Gene Sets Sharing Transcription Factor Binding Sites,
By Transcription Factor
YY1 2.1095614 0
E2F 2.0739126 0.00629868
E2F 2.0437264 0.00472401
SREBP1 2.0296636 0.003779208
E2F 1.9984082 0.004686787
NRF1 1.9882506 0.004166033
E2F 1.973179 0.003408572
NRF2 1.9532624 0.004709931
E2F 1.944042 0.004037084
ETS1 1.9379699 0.004403604
E2F 1.931731 0.004128379
E2F 1.9269646 0.003885533
E2F 1.926879 0.00366967
E2F 1.8943775 0.003984813
E2F 1.8883003 0.003785573
E2F 1.8871185 0.003605307
E2F 1.8828987 0.00344143
E2F 1.8726895 0.003154644
E2F 1.8725656 0.00339813
E2F 1.8696322 0.003146417
PAX3 1.8358319 0.003565615
GABP 1.8336416 0.003446761
E2F 1.826765 0.003335575
Table 1. Continued
Gene Sets enriched by Interaction
between IM and LBH NES FDR q-val
MYCMAX 1.8066974 0.003531206
ELK1 1.8054509 0.003711315
Gene expression programs in CML CD34+CD38 cells that were selec-
tively altered by interaction between LBH and IM were identified and
categorized. Gene sets representing common functional categories
were grouped as shown in Figure 7B. The top two gene sets representa-
tive of each of these groups (ranked by FDR) are shown in the top half of
the table. Gene sets sharing common transcription factor (TF) binding
sites that were selectively altered in CML CD34+CD38 cells by interac-
tion between LBH and IM were identified. The top 25 sets based on FDR
are shown in the bottom half of the table. NES, normalized enrichment
score; FDR, false discovery rate.
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440 Cancer Cell 17, 427–442, May 18, 2010 ª2010 Elsevier Inc.Bioconductor (version 2.4). Expression data were normalized with the robust
multiarray average (RMA) algorithm, with background adjustment, quantile
normalization, and median polish summarization. Probe sets with low expres-
sion levels or low variability across samples were filtered. For genes with
multiple probe sets, the gene level expression was set to be the median of
the probe sets. Linear regression was used to model the gene expression
with the consideration of 2 3 2 factorial design and matched samples. Differ-
entially expressed genes were identified by calculating empirical Bayes
moderated t-statistic, and p values were adjusted by FDR with the ‘‘LIMMA’’
package. We focused our attention on the ‘‘interaction’’ between IM and
LBH to identify genes for which the extra effect of the combination of IM
and LBH is significant—that is, the additional effect of the combination drug
that cannot be explained by the additive effect of IM and LBH treatment:
Interaction = (Combination  LBH)  (IM  Control). Genes significantly
altered by interaction between IM and LBH (p < 0.01; fold change, 3) were
selected. Gene Set Enrichment Analysis (GSEA) was performed with GSEA
software version 2.04 (http://www.broadinstitute.org/gsea/) for detection of
enrichment of predetermined gene sets with t-scores from all 13,812 genes
for 1,263 gene sets in C2 (curated gene sets) category from the Molecular
Signature Database (MsigDB) (Subramanian et al., 2005). Gene sets repre-
senting common functional categories were categorized and grouped.
We also analyzed enrichment of gene sets with common TF binding sites
(586 sets) from MsigDB.
Statistics
Data from independent experiments were reported as the mean ± SEM.
Student’s t test analysis was performed to determine statistical significance.
ACCESSION NUMBER
Microarray data have been deposited in the Gene Expression Omnibus data-
base (accession number GSE20876).
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Supplemental information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
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